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Introduction: COPD exacerbations are associated with a concomitant profound reduction 
in daily physical activity (PA). Thereby, exacerbation frequency and severity may have an 
amplifying effect. Whether the reduced level of PA returns to the level prior to exacerbation or 
has a sustained negative impact on activity behavior over time is unclear.
Methods: The number of steps per day over 1 week, as a measure of daily PA, was assessed 
annually in a cohort of patients with COPD. Exacerbation frequency and severity were docu-
mented. Uni- and multivariate mixed effect models were used to investigate associations between 
change in number of steps per day (dependent variable) and exacerbations. Stratification by 
possible confounders was performed.
Results: One hundred and eighty one COPD patients (median [quartile] age 64 [59/69] years, 
65% male, median [quartiles] FEV
1
 % pred. 46 [33/65]) suffered a total of 273 exacerbations 
during the observation period (median [quartiles] follow-up time of 2.1 [1.6/3.1] years). Neither 
the frequency nor the severity of exacerbations was significantly related to the overall decline 
in PA over time. Stratification by different possible confounders such as age, sex and disease 
severity did not yield a subgroup in which exacerbations enhance the decrease in PA over time.
Conclusion: The drop in PA during the phase of an acute exacerbation seems not to be a last-
ing phenomenon leading to a fundamental change in activity behavior.
Trial registration: www.ClinicalTrials.gov, NCT01527773
Keywords: COPD, daily physical activity, exacerbation
Introduction
Acute exacerbations (AEs) of COPD are clinically characterized by a sustained 
worsening of patients’ condition (increase of dyspnea, cough and/or sputum) beyond 
normal day-to-day variation.1 Previous studies have shown a negative impact of AE 
on various health-related outcomes in patients with COPD. These include a reduced 
pulmonary function, an impaired quality of life and a worse survival.2–4 Therefore, 
AEs are recognized as an important factor predicting poor outcome in COPD patients.
Daily physical activity (PA) is acutely reduced in patients suffering from severe 
exacerbations requiring hospitalization5 as well as in patients treated for exacerba-
tions in an ambulatory setting.6,7 Epidemiological studies have shown that a low level 
of PA is an important prognostic marker in COPD. Some of these studies suggest 
that patients practicing regular PA reduce their risk of hospital admission due to 
AE.8–10 Esteban et al11 demonstrated that exacerbation-related decrease in PA is the 
best predictor of 1-year risk of mortality in over 1,800 COPD patients enrolled in a 
prospective observational cohort study.
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A previous study by our group investigated the natural 
course of daily PA over time and possible predictors.12 
There was no significant difference in PA decline between 
patients with frequent exacerbations ($2 exacerbations/year) 
and nonfrequent exacerbations (0–1 exacerbations/year). 
Recently published data on the effect of COPD exacerba-
tions, especially the severity of exacerbations, on the decline 
in daily PA within 1 year revealed a possible acceleration by 
moderate and severe exacerbations.13 To verify these find-
ings, the objective of the present analysis was to investigate 
the association between frequency and severity of exacer-
bations and changes in PA over time in our COPD cohort.
Methods
study design and subjects
In the longitudinal, prospective cohort study “The Obstruc-
tive Pulmonary Disease Outcomes Cohort Study” patients 
with mild to very severe COPD were included from seven 
Swiss pulmonary outpatient clinics. Recruitment period 
was between October 2010 and December 2015. Patients 
were asked to participate during outpatient visits or during 
hospital stays for initially three annual study visits (some 
patients agreed to participate up to 7 years). The study was 
finished in December 2016 after the last recruited patients 
performed at least one follow-up visit. This manuscript 
analyses data out of this cohort and only patients with at 
least one follow-up measurement were included. Inclusion 
criteria were defined as 1) 40 to 75 years old at inclusion 
and 2) confirmed COPD according to GOLD guidelines.14 
Patients who suffered from mental or physical disability 
precluding informed consent or compliance with the 
protocol were excluded. In case of an acute COPD exac-
erbation at time of screening or yearly follow-up, visits 
were performed with a delay of at least 6 weeks in an 
exacerbation-free interval.
The study was conducted in accordance with the 
Declaration of Helsinki, and all subjects gave written 
informed consent to participate. The Ethics Committee 
of the Canton of Zurich approved the study (EK-ZH-NR: 
1734 and 2011-0106). The study registration number at 
www.ClinicalTrials.gov is NCT01527773.
Measurements
assessment of daily Pa
The number of steps per day was assessed by a triaxial 
accelerometer of a multisensory armband (SenseWear Pro™; 
Bodymedia Inc., Pittsburgh, PA, USA). The sensor had to be 
worn on the upper left arm over the triceps muscle.15
The number of steps per day was annually recorded 
over 7 consecutive days. A minimum of 4 days with at least 
22.5 hours/day was demanded to be included in the analysis.16 
Due to the longitudinal setting of this study, intensity of PA 
(eg, time spent at moderate activity) was not included in this 
analysis since disease progression over time possibly increases 
energy expenditure for same activity tasks and therefore could 
overestimate intensity of PA. Fifteen patients were excluded 
from the analysis due to missing PA values (technical reasons, 
armband not worn), six patients failed to reach the demanded 
wearing time and two patients performed an allergic reaction 
to the armband. Seasonality was considered in the analysis.
exacerbations
The number and severity of AE during the preceding year 
were assessed by medical reports and asking patients them-
selves. If exacerbation history did not match between patient 
and medical records, we contacted the general practitioner 
and/or external pulmonologist for clarification. AE was 
defined as an event which led to prescription of antibiot-
ics and/or corticosteroids.17 Severity of AE was defined as 
follows: moderate exacerbation (treated in an ambulatory 
setting) and severe exacerbation (AE led to hospitalization). 
For exacerbation categories, patients with moderate and 
severe exacerbations within the same year were categorized 
as severe. Patients with infrequent exacerbations were con-
sidered to have 0–1 AE per year, whereas patients with $2 
AE per year were defined as frequent exacerbators.18
lung function
Standard pulmonary function testing was performed to mea-
sure FEV
1
 and FVC according to ATS guidelines.19,20 Only 
values after bronchodilation were analyzed. Disease sever-
ity was categorized by spirometric GOLD stages (1–4) and 
COPD risk groups (A [low risk, less symptoms] to D [high 
risk, more symptoms]).21 The modified medical research coun-
cil (mMRC) scale22 was used to assess dyspnea and the COPD 
Assessment Test (CAT)23 to assess disease specific symptoms.
Data analysis and statistics
Results are shown as mean values (SD) or median (Q1-quartiles/ 
Q3-quartile) unless otherwise stated. Statistical analysis was 
performed with STATA 15.0 (StataCorp, College Station, 
TX, USA).
Uni- and multivariate mixed effect models were used to 
investigate the association between annual change in num-
ber of steps per day (dependent variable) and exacerbation 
parameters, accounting for possible confounders (e.g., sex, 
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disease severity). To investigate the possibility that exacer-
bations may influence the course in daily PA at about the 
same time or with a delay, all analyses were performed with 
exacerbations parameters from 1) the corresponding follow-
up period and 2) from the year prior to examination.
To check the regression assumptions, residual analysis 
of the model was performed.
A two-sided P-value of ,0.05 was considered to be 
statistically significant.
Results
study participants
Three hundred thirteen patients were included at baseline, 
whereof 181 COPD patients (45% spirometric GOLD 
stage 1/2, 38% GOLD 3 and 16% GOLD 4) entered this 
analysis (Figure 1). Follow-up time was median (quartiles) 
2.1 (1.6/3.1) years with a minimum of one follow-up visit and a 
maximum of seven annual follow-up visits. During follow-up, 
127 patients were analyzed at year 3 and 48 at year 4. 
Sixty-five percent of the COPD patients were male, median 
(quartiles) age was 64 (59.0/69.0) years. Further patient 
characteristics are presented in Table 1. Reasons for miss-
ing first or second follow-up visit were withdrawal, not able 
to participate anymore due to worsening health status, lung 
transplantation, moving abroad, lost to follow-up and death.
At baseline, 67 out of 181 patients (37%) suffered from at 
least one exacerbation in the previous year, 14% of patients 
were classified as frequent exacerbators. In total, there were 
273 exacerbations during the observation period, 55 of them 
led to hospital admissions.
In this cohort, the mean (95% CI) number of steps per day 
significantly decreased by annually -479.1 (-634.2/-324.1) 
steps, P,0.001. Patients who were followed-up did not 
show any differences in exacerbation frequency and daily 
PA compared to patients who failed to follow-up.
exacerbations within the particular year 
of observation
The number of exacerbations during the year had no influence 
on the decline in number of steps per day (mean Coef. 
&23'SDWLHQWGDWDDQDO\]HGDW)8
&23'SDWLHQWGDWDDQDO\]HGDW)8
&23'SDWLHQWGDWDDQDO\]HGZLWKDWOHDVWWZRPHDVXUHPHQWV
&23'SDWLHQWLQFOXGHGDWEDVHOLQH
5HIXVHGSDUWLFLSDWLRQ:RUVHQLQJRIKHDOWKVWDWXV'HDWK/XQJWUDQVSODQWDWLRQ1RYDOLG6HQVH:HDUGDWD
5HIXVHGSDUWLFLSDWLRQ:RUVHQLQJRIKHDOWKVWDWXV'HDWK/XQJWUDQVSODQWDWLRQ1RYDOLG6HQVH:HDUGDWD6WXG\ILQLVKHG
5HIXVHGSDUWLFLSDWLRQ:RUVHQLQJRIKHDOWKVWDWXV'HDWK/XQJWUDQVSODQWDWLRQ$EURDG/RVWRIIROORZXS1RYDOLG6HQVH:HDUGDWD
Figure 1 Study flow.
Abbreviation: FU, follow up.
Table 1 Patient characteristics at baseline
N=181
age, years 64.0 (59.0/69.0)
Male/female, n 117/64
BMI, kg/m2 25.8 (22.6/28.3)
never smoker/current smoker/former 
smoker, n
7/44/130
Pack years of smoking, n 40 (30/60)
lung function
FVC, % pred. 82 (20.7)
FeV1, % pred. 46 (33.0/65.0)
COPD risk group, n (%)
a 31 (17)
B 89 (49)
C 9 (5)
D 52 (29)
number of exacerbations previous year, 
n/patient
0 (0/1)
exacerbation category
no exacerbation, n (%) 113 (62)
Moderate exacerbation, n (%) 43 (24)
severe exacerbation, n (%) 25 (14)
Daily physical activity
number of steps per day, n 4,626 (2,884/7,220)
Notes: Values are median (quartiles) or mean (sD) unless otherwise stated. COPD 
risk group a (low risk, less symptoms), B (low risk, more symptoms), C (high risk, 
less symptoms), D (high risk, more symptoms).
Abbreviation: BMI, body mass index.
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Figure 2 exacerbation categories and change in number of steps per day over time.
Notes: The adjusted for baseline change in number of steps per day over time 
of exacerbation categories (no exacerbation/moderate exacerbation/severe 
exacerbation) is illustrated. It reveals a nonsignificant but slightly greater decline in 
daily Pa over time in patients with at least one severe exacerbation.
Abbreviation: Pa, physical activity.
6,000
4,000
2,000
0
0 1 2
Annual visit
St
ep
s 
pe
r d
ay
 (N
)
3 4
No exacerbation
Moderate exacerbation
Severe exacerbation
Table 2 Multivariate regression analysis of exacerbation category (suffered within the particular year of observation) and annual 
change in number of steps per day
Exacerbation category Coef. 95% CI P-value Coef.a 95% CIa P-valuea
a) no exacerbation (reference)
Moderate exacerbation -387.9 -909.9/134.2 0.145 68.7 -290.5/427.8 0.708
severe exacerbation -16.6 -1,028.5/995.4 0.974 -360.1 -1,044.6/324.4 0.303
B) no exacerbation (reference)
1 moderate exacerbation -422.0 -1,003.0/159.0 0.155 21.4 -344.3/387.2 0.909
$2 moderate exacerbations -266.5 -1,000.6/467.7 0.477 334.7 -183.3/852.7 0.205
$1 severe exacerbation -38.1 -1,050.0/973.8 0.941 -273.4 -964.0/417.3 0.438
Note: aadjusted for baseline number of steps per day.
[95% CI] -18.4 [-250.9/214.1], P=0.877), even after 
adjusting for baseline number of steps (P=0.245). There was 
no significant difference in change in number of steps per day 
between exacerbation categories (no exacerbation/moderate 
exacerbation/severe exacerbation) (Table 2A). Adjusting for 
baseline number of steps per day revealed a slightly greater 
decline in daily PA over time in patients with at least one 
severe exacerbation. However, it did not reach statistical 
significance (Table 2A and Figure 2).
Exacerbation categories (no exacerbation, 1 moder-
ate exacerbation, $2 moderate exacerbations, $1 severe 
exacerbation) in accordance to Demeyer et al13 showed no 
significant difference in change in number of steps per day 
over time, unadjusted and adjusted for baseline number of 
steps per day (Table 2B).
Furthermore, the decline in number of steps per day 
over time was not significant different between frequent 
exacerbators and infrequent exacerbators (mean Coef. 
[95% CI] -136.9 [-746.9/473.1], P=0.660; mean Coef. 
[95% CI] adj. for baseline number of steps per day 241.9 
[-179.9/663.6], P=0.261).
exacerbations in the year prior to the 
year of observation
The annual change in number of steps per day was not influenced 
by the number of exacerbations in the previous year (mean 
Coef. [95% CI] -58.4 [-189.3/72.5], P=0.382). Furthermore, 
there was no significant difference in annual change in number 
of steps per day between different exacerbation–severity 
categories (no exacerbation/moderate exacerbation/severe 
exacerbation and no exacerbation/1 moderate exacerbation/$2 
exacerbations/$1 severe exacerbation, respectively) 
(Table 3A and B). Frequent exacerbators did not show 
a significant different annual change in number of steps 
per day compared to infrequent exacerbators (mean Coef. 
[95% CI] -192.9 [-538.6/152.8], P=0.274).
Adjusting for baseline number of steps did not yield any 
changes in our findings.
Stratification by possible confounders
Neither age, sex, body mass index, airway obstruction 
(GOLD stages), seasonality of PA assessment, number of 
comorbidities nor COPD risk category revealed a subgroup 
in which exacerbation profile is associated with a decline in 
number of steps per day. Although COPD-related symptoms 
(mMRC and CAT) significantly increased over time, there 
was no influence on the annual decline in number of steps 
per day, irrespective of exacerbation category. Furthermore, 
there seems to be no healthy survivor effect since there was 
no different associations between exacerbation categories 
and change in number of steps per day in patients who died 
within or after the study period (last update in November 
2017) and patients who survived.
Discussion
This study investigated the hypothesis whether the frequency 
and severity of exacerbations influence PA in patients with 
COPD over a period of up to 7 years. We found that neither 
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Table 3 Multivariate regression analysis of exacerbation category (suffered in the year prior to the year of observation) and annual 
change in number of steps per day
Exacerbation category Coef. 95% CI P-value Coef.a 95% CIa P-valuea
a) no exacerbation (reference)
Moderate exacerbation -69.2 -373.3/234.8 0.655 -37.1 -310.8/236.5 0.790
severe exacerbation -100.7 -587.6/386.3 0.685 -120.6 -567.5/326.3 0.597
B) no exacerbation (reference)
1 moderate exacerbation -37.2 -388.2/313.8 0.835 -55.2 -357.3/247.0 0.720
$2 moderate exacerbations -153.9 -561.1/253.3 0.459 -36.2 -410.8/338.3 0.850
$1 severe exacerbation -127.5 -620.5/365.6 0.612 -132.3 -586.3/321.7 0.568
Note: aadjusted for baseline number of steps per day.
the number nor the severity of exacerbations was related to 
the overall decline in PA over time. This study shows that 
although a considerable drop of PA has been attributed to the 
phase of an AE in previous studies, this decline seems not to 
be a lasting phenomenon leading to a fundamental change 
in activity behavior.
AEs are known to have an important impact on the 
quality of life and mortality in patients with COPD. It can 
take several weeks until respiratory symptoms are back to 
baseline.24 Although a deteriorating of respiratory symptoms 
is by definition a key feature of an AE, several additional 
observations can be made such as a profound reduction of 
daily PA. In a prospective study of almost 2,500 COPD 
patients, Esteban et al11 reported that after a moderate to 
severe COPD exacerbation, a failure to recover the level of 
PA (baseline to 2 months after the event assessed by ques-
tionnaire) had an important negative impact on survival at 
the 1-year follow-up.
Alahmari et al6 assessed daily step count prior, during 
and after AE in 73 COPD patients and found a median step 
count of 198 days per patient. Daily step-count returned to the 
level prior to AE within a median (interquartile range) of 3.5 
(1–8) days. A larger fall in daily step count at exacerbation 
implicates a longer period to return to the normal activity 
level. Some studies showed a prolonged recovery time to 
initial daily PA level or even no return to baseline level.5,11 A 
study with 17 COPD patients admitted to hospital due to AE 
revealed a reduced time on weight-bearing activities (walking 
and sitting) not only during hospitalization but also 1 month 
after discharge when compared to stable COPD patients.5
Demeyer et al13 recently report the results of a larger 
cohort consisting of 141 COPD patients, looking at PA (by 
accelerometer) and number and severity of COPD exacer-
bations. Two or more moderate exacerbations or a severe 
exacerbation led to a significant greater decline in daily step 
count after 1 year compared to patients without exacerbations. 
In our cohort these findings could not be confirmed. Patients 
with more frequent or severe exacerbations were not prone 
to an accelerated annual decline in PA. Comparing patients 
with severe exacerbations to the ones with no or moderate 
exacerbations showed qualitatively a slightly greater decrease 
that was however not statistically significant (Figure 2). 
It could be hypothesized that after a severe exacerbation 
these patients might almost but not fully reach their level 
of daily PA prior to hospitalization. However, there is only 
one study investigating the minimal important difference 
(MID) in number of steps per day in patients with COPD. 
In 74 patients, MID was set between 600 and 1,100 steps 
per day.25 Therefore, it is not possible to conclude if this slightly 
greater decrease reports an MID despite nonsignificance.
Different considerations have to be taken into account 
when comparing both cohorts. The observation time relies on 
two time points (measurement at baseline and at 12 months’ 
follow-up) in the analysis by Demeyer et al.13 In our cohort, 
patients were observed up to 7 years. Further, PA did not 
decline in their cohort while our patients showed a signifi-
cant annual decline in daily steps over time. This decline 
corresponds approximately to the decline of PA described by 
Waschki et al.26 Overall, our cohort was slightly less active. 
However, the different findings between both studies cannot 
be explained by this fact since all results were also adjusted 
for baseline PA.
The hypothesis that an increase in COPD related 
symptoms (assessed by mMRC or CAT) as a consequence of 
more frequent exacerbations may lead to a downward spiral 
resulting in a lower level of daily PA cannot be confirmed in 
our cohort. Therefore, further longitudinal analysis including 
the whole spectrum of COPD patients is needed to determine 
the effect of exacerbations on the level of PA over time.
A limitation of this study is that we cannot exclude that 
some patients underwent pulmonary rehabilitation after a 
severe exacerbation weakening the effect of exacerbation 
on decline in PA. However, duration between pulmonary 
rehabilitation and measurement can be assumed as random 
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and patients were measured with a delay of 6 weeks after 
exacerbations. Furthermore, the effect of pulmonary reha-
bilitation on PA beyond 3 months is unclear;27 thus, we 
think it will not influence our results. Exacerbation dura-
tion and time between exacerbations and study visits were 
not analyzed, although a shorter time interval between last 
exacerbation and study visit could have influenced the 
number of steps per day in the individual patient. Due to 
the high number of exacerbations during the observation 
period, we assume that they are evenly distributed among a 
study year and therefore show no impact on our results. This 
COPD cohort study was designed to characterize COPD 
patients with annual follow-ups. Therefore, no sample size 
calculation was performed a priori for our outcomes. A lack 
of significance of some predictors (e.g., severe exacerba-
tions) cannot be excluded due to a possible small number 
of events each year.
In conclusion, the findings of the current study do not 
support the hypothesis that frequency and severity of exac-
erbations have a significant impact on the decline of daily 
PA over time.
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